News releases | Absci Corp

Year

07 Mar / 23

Absci to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

VANCOUVER, Wash. and NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating virtually in the upcoming KeyBanc Capital Markets Life Sciences & MedTech Investor Forum.

28 Feb / 23

Absci Expands in Europe with Launch of New Innovation Center and Additional Senior Leadership in Switzerland

The generative AI drug company ramps up its internal pipeline and R&D portfolio, tapping into European markets, talent, and tech VANCOUVER, Wash. and NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced its expansion

21 Feb / 23

Absci to Participate in the 43rd Annual Cowen Health Care Conference

VANCOUVER, Wash. and NEW YORK, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming 43 rd Annual Cowen Health Care Conference. Absci’s management is scheduled to participate in a

09 Feb / 23

St. John’s Cancer Institute Partners with Absci to Expedite Development of Cancer Therapies

Absci’s generative AI and wet lab capabilities combined with St. John’s Cancer Institute’s molecular database of cancer patient specimens will accelerate the development of immunotherapies. VANCOUVER, Wash. and NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a

08 Feb / 23

Absci Deepens Scientific Advisory Board to Accelerate Generative AI Drug Creation

In silico antibody design expert Dr. Victor Greiff, synthetic biology pioneer Dr. Timothy Lu, and translational medicine veteran Dr. Hubert Truebel will strengthen Absci’s scientific leadership in biologic drug creation. VANCOUVER, Wash. and NEW YORK, Feb.

10 Jan / 23

Absci First to Create and Validate De Novo Antibodies with Zero-Shot Generative AI

This breakthrough unlocks the potential to accelerate time to clinic by over 50% and increase probability of success in the clinic Creating antibodies in silico with generative AI represents a major industry breakthrough on the path to fully de novo antibody design and Absci’s vision to deliver

08 Jan / 23

Absci to Participate in the 41st Annual J.P. Morgan Healthcare Conference

VANCOUVER, Wash. and NEW YORK, Jan. 08, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming 41 st Annual J.P. Morgan Healthcare Conference in San Francisco, CA.